Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — TRxADE HEALTH — Investor Presentation (March 2023)
14 slides from Scienture's investor presentation, Mar 27, 2023
Slide 1: Digitalizing the Retail Pharmacy Experience
@TRADE Digitalizing the Retail Pharmacy Experience . » Investor Presentation - March 2023 - sonal
Slide 2: Safe Harbor Statement
Safe Harbor Statement ‘This presentation contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, ineluding the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 taements that se nt historical ae forward-loo
Slide 3: About TRxADE HEALTH, INC.
About TRxADE HEALTH, INC. TRXADE is a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. Market Leader: Operates one of the largest technology marketpla
Slide 4: Divisions of TRXADE HEALTH
Divisions of TRXADE HEALTH Pharmaceutical Marketplaces (With Supporting B2B + Supporting Subsidiaries): B2 ‘ a Business to Business \ Robust procurement technology platform that delivers a lower cost and transparent procurement process for independent pharmacists and clinics compared to industry nor
Slide 5: TRxADE Marketplace
TRxXADE Marketplace Our B2B Pharmaceutical Supply Chain Platform U.S. Pharmaceutical Industry!? + Projected $685B per year industry size by 2023 and growing; Over 65,000 pharmacy facilities * Approximately 9 out of 10 Americans live within 5 miles of a community pharmacy + Excluding several large na
Slide 6: TRxADE Marketplace
TRxXADE Marketplace Trxade.com (Distributor Pharmaceutical Supply Chain Platform) Our Marketplace Solution *TRxADE’s exchange platform offers a clear and concise interface that allows over 14,400+ registered members in 50 states to analyze “up- to-the-minute” supply & pricing from multiple pharma su
Slide 7: Selected Operational Metrics
Selected Operational Metrics TRXxADE Platform Our marketplace has over 72 national and regional pharmaceutical suppliers providing over 120,000 branded and generic drugs, including over the counter drugs and drugs available for purchase by pharmacists. Metrics for the twelve-month period ending Dece
Slide 8: Selected Financials
Selected Financials + High Margin: Revenue from transaction fees on marketplace platform (Credit Card/PayPal model) does not include the drugs value (over $100M annually), hence “tech like margins” + Built-Out Platform: 14,400+ registered members with continued platform development requiring minimal
Slide 9: Management
Management Suren Ajarapu, Chairman of the Board and Chief Executive Officer Mr Alarapu has served as Charman of the Board, Chief Executive Officer and Secretary since our acquisition of Trade Group, nc, a Nevada corporation (“TRADE Nevada") (our predecessor Company) on January 8, 2014, and asthe Cha
Slide 10: Key Takeaways
10 Key Takeaways NASDAQ:MEDS TRXADE is a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. A Tech Focused Healthcare Services Company Market Leader: Op
Slide 11: Contact Us
Contact Us TRxADE HEALTH, INC. 2420 Brunello Trace Lutz, FL 34558 (800) 261-0281 www.trxadehealth.com @TRADE
Slide 12: Appendix: Consolidated Balance Sheet
Appendix: Consolidated Balance Sheet TRLADE HEALTH, INC. December 3, 222 and December 81,2021 g i 5 sass 8 i i i i a A | g | i i 2 omg ig abies | 2 —Othrlomgerminiibes Hewes ans ts Sean . 33a See A pofred stk S000 pr ls: 1.00100 se ut St ‘ote 5 | | g @TRADE
Slide 13: Appendix: Consolidated Statement of Operations
Appendix: ‘TRxADE HEALTH, INC. Consolidated Statement of Operations For the Years Ended December 31, 2022 and 2021 Consolidated Statements of Operations Years Ended December 31, 2022 2021 Revenues S 11488265 9,880,433 Cost of Sales 5,997,049 5,143,468 Gross Profit 5,451,216 4.745.965 Operating Expen
Slide 14: Reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA
Reconciliation of Net Income(Loss) attributable to TRxADE HEALTH, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA* Appendix: ‘Net loss attributable to TRxADE Health, Inc. $ (3,472,095) $ (5,315,883) Aad edu) ine it 31s217 ae Depreciation an armtiz